Item 8.01 Other Events.

On April 30, 2020, Acceleron Pharma Inc. (the "Company") and Bristol Myers Squibb Company issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending the approval of REBLOZYL® (luspatercept) for the treatment of:



•      Adult patients with transfusion-dependent anemia due to very low-, low-
       and intermediate-risk myelodysplastic syndromes (MDS) with ring
       sideroblasts, who had an unsatisfactory response or are ineligible for
       erythropoietin-based therapy.



•      Adult patients with transfusion-dependent anemia associated with beta
       thalassemia.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On May 4, 2020, the Company issued a press release announcing that the EMA has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
Number                             Description of Exhibit
            Press Release of Acceleron Pharma Inc. and Bristol Myers Squibb
99.1      Company dated April 30, 2020
99.2        Press Release of Acceleron Pharma Inc. dated May 4, 2020
          Cover Page Interactive Data File (embedded within the Inline XBRL
104       document)




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses